Chemotherapy-related adverse effects with anthracycline and taxane-containing regimens in patients with localized Breast cancer: a descriptive study
Abstract Background Although the side effects of chemotherapy are frequently described in research studies, there is little evidence on how common they are in everyday clinical care. This study’s goal was to assess the most prevalent short-term side effects experienced by patients with localized bre...
Main Authors: | Farah Choulli, Hassan Abdelilah Tafenzi, Faiçal EL Hattimy, Mohamed Khaled Choulli, Rhizlane Belbaraka |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-01-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-023-11616-5 |
Similar Items
-
ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers
by: Tarek M. A. Abdel-Fatah, et al.
Published: (2019-08-01) -
Oral vinorelbine: its role in advanced breast cancer pre-treated with anthracycline and taxane chemotherapies
by: Fausto Petrelli, et al.
Published: (2011-12-01) -
Resistance to Combined Anthracycline–Taxane Chemotherapy Is Associated with Altered Metabolism and Inflammation in Breast Carcinomas
by: Otília Menyhárt, et al.
Published: (2024-01-01) -
Four Cycles of Docetaxel-Cyclophosphamide versus Anthracycline-Taxane as Adjuvant Chemotherapy for HER2-Negative, Axillary Lymph Node Negative Breast Cancer: A Real-World Comparison of Alberta Patients Treated 2008–2012
by: Malek Hannouf, et al.
Published: (2021-03-01) -
Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial
by: Houpu Yang, et al.
Published: (2022-12-01)